Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.

Landgren O, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis R, Carson R, Hofmeister CC

Open source

DOI: 10.1182/blood.2024025897
Published: 2025 Apr 10
Container: Blood
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2024025897,
  title = {Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.},
  author = {Landgren O and Chari A and Cohen YC and Spencer A and Voorhees PM and Sandhu I and Jenner MW and Smith D and Cavo M and van de Donk NWCJ and Beksac M and Moreau P and Goldschmidt H and Vieyra D and Sha L and Li L and Rousseau E and Dennis R and Carson R and Hofmeister CC},
  year = {2025},
  journal = {Blood},
  doi = {10.1182/blood.2024025897},
  url = {https://doi.org/10.1182/blood.2024025897}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.
AU  - Landgren O
AU  - Chari A
AU  - Cohen YC
AU  - Spencer A
AU  - Voorhees PM
AU  - Sandhu I
AU  - Jenner MW
AU  - Smith D
AU  - Cavo M
AU  - van de Donk NWCJ
AU  - Beksac M
AU  - Moreau P
AU  - Goldschmidt H
AU  - Vieyra D
AU  - Sha L
AU  - Li L
AU  - Rousseau E
AU  - Dennis R
AU  - Carson R
AU  - Hofmeister CC
PY  - 2025
JO  - Blood
DO  - 10.1182/blood.2024025897
UR  - https://doi.org/10.1182/blood.2024025897
ER  -

APA

O, L., A, C., YC, C., A, S., PM, V., I, S., MW, J., D, S., M, C., NWCJ, V. D. D., M, B., P, M., H, G., D, V., L, S., L, L., E, R., R, D., R, C., & CC, H. (2025). Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.. Blood. https://doi.org/10.1182/blood.2024025897

Source records

pubmed · retrieved 2026-09-26T07:37:22.648Z